BMO Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1101
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Eli Lilly (NYSE:LLY) and raises the price target from $1001 to $1101.
August 09, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Eli Lilly and raises the price target from $1001 to $1101.
The raised price target and maintained Outperform rating from BMO Capital are positive signals for Eli Lilly's stock, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100